Cowen analyst Charles Ryhee raised the firm’s price target on Evolent Health (EVH) to $59 from $57 and keeps an Outperform rating on the shares. The analyst updated the firm’s to incorporate the recently announced Humana (HUM) contract win and the closing of its NIA acquisition which closed 2 months earlier than our model previously assumed. The Hjumana contract which goes live 2H23, is expected to bring $250M in annualized revenue.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EVH:
- Centene completes divestiture of Magellan Specialty Health to Evolent Health
- Evolent Health jumps after announcing expansion of Humana pact
- Evolent Health price target raised to $51 from $44 at Piper Sandler
- Evolent Health management to meet with BTIG
- Evolent Health price target raised to $44 from $33 at Piper Sandler